Name That Brand: June 2012

Share this article:

Can you name the brand? Each month we print part of a popular pharmaceutical product or advertisement, with clues to its identity. Readers are invited to name the brand for a chance to win a copy of Medicine Ave 2: The Story of Medical Advertising in America 1990-2008. E-mail your answer to or fax 646-638-6150. The deadline is May 31, 2012. The winner will be picked randomly from the correct entries.

Brand X tries to reinforce its sales
This brand is all about strength, but the FDA and analysts say this drug isn't meant to have a future of limitless spin-offs. It's sad news for the drug's franchise, which has suffered from slow growth, although an advertising campaign for another indication, featuring a boomer actress, has boosted site traffic more than six-fold. Despite the sluggish start, the company said last year projected global sales of the fortifying drug somewhere in the neighborhood of $3-$4 billion by 2015.

No one was able to correctly identify April's Name That Brand. The answer was Pfizer's Lyrica, which is indicated to treat fibromyalgia, diabetic nerve pain and pain after shingles.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?